Human prostaglandin reductases dearomatize and inactivate benzothiazinone antitubercular drugs
Decosterd, L. A.; Briki, M.; Wagner, C.; Desfontaine, V.; Vocat, A.; Opota, O.; Abou-Zite, S.; Corpataux, O.; Cena, B.; Guinchard, S.; Versace, F.; Murisier, A.; Mercier, T.; Blattes, E.; Bardinet, C.; Thoueille, P.; Wsol, V.; Chtioui, H.; Rothuizen, L.; Nahimana, A.; Bellotti, A.; Chiarelli, L. R.; Spaggiari, D.; Dhar, N.; Mishra, R.; Sommer, R.; Lupien, A.; Duchosal, M. R.; Guery, B.; Girardin, F.; Milano, G.; Ryabova, O.; Makarov, V.; Buclin, T.; Cole, S. T.; Choong, E.
Show abstract
Macozinone (MCZ, PBTZ169) is a potent clinical stage benzothiazinone antitubercular agent that covalently inhibits the essential mycobacterial flavoenzyme DprE1. In some mammals, MCZ undergoes reductive dearomatization to H2MCZ, a Hydride Meisenheimer Complex, identified as the major circulating metabolite in humans. We demonstrate for the first time that the NADPH-dependent human prostaglandin reductases PTGR1 and PTGR2 catalyze MCZ dearomatization into H2MCZ, resulting in loss of antimycobacterial activity. This reaction represents a heretofore undescribed host-mediated metabolic inactivation pathway for a therapeutic agent. Although H2MCZ may constitute a transient reactive intermediate, ex vivo and cellular data indicate that it does not contribute to DprE1 inhibition in vivo. Pharmacological inhibition of PTGR1 and PTGR2 using diclofenac, indomethacin, dicumarol, or the selective inhibitor PTGR2-IN-1 suppresses H2MCZ formation and partially restores MCZ antimycobacterial activity in vitro. Together, our findings uncover a previously unrecognized noncanonical enzymatic mechanism of drug metabolism involving dearomatization in humans. Targeting prostaglandin reductases may represent a strategy to enhance benzothiazinone exposure and efficacy.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern 91%
- The human hepatocyte TXG-MAPr: WGCNA transcriptomic modules to support mechanism-based risk assessment 90%
- Identification of Functional Genetic Components Modulating Toxicity Response to PFOS using Genome-wide CRISPR Screens in HepG2/C3A cells 90%
Similar papers in this journal
- A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis 94%
- Pharmacological complementation remedies an inborn error of lipid metabolism 93%
- Morphological Subprofile Analysis for Bioactivity Annotation of Small Molecules 93%
Similar papers in this journal
- Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms 93%
- Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria 92%
- A Systematic Assessment of Robustness in CNS Safety Pharmacology 90%
Similar papers in this journal
Similar papers in this journal
- Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs 94%
- Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies. 92%
- Chemoproteomic profiling reveals cellular targets of nitro-fatty acids 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.